NBIX · Investment summary · as of 12 August 2026
Priced below what the business already delivers
Business type: Compounder · mature and structurally stable
Size is the strategy's, set against its own position and exposure limits.
At $156.49, NBIX requires a 4% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 34%.
Estimates have moved fY2026 revenue consensus $3,792.2m -> $3,901.5m (up), FY2026 EPS $9.96 -> $10.17 (up); FY2027 revenue $4,494.3m -> $4,568.4m (up), FY2027 EPS $12.66 -> $12.17 (down — the raised spend guide flows into FY2027 EPS). HOUSE TARGET $199.44 IS below STREET'S $213.13 AND THE ENTIRE GAP IS THE MULTIPLE: Street's average implies 4.83x EV/NTM-sales (their own revenue, same forward net cash) = the median of NBIX's own forward history; house uses 4.50x (~38th pctile) for the spend-guide/IRA de-rating.
The strongest argument against this view: the Zydus Paragraph IV challenge to INGREZZA SPRINKLE breaks the settled 1 March 2038 generic wall years early on a franchise that is 80.5% of TTM revenue ($2,717.5m of $3,373.9m; $716.5m of $959.0m in Q2 2026 = 74.7%).
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | FY2021-FY2025 GAAP operating margin 9.0/16.7/13.3/24.2/21.6%; TTM to 30 June 2026 23.56%. TTM operating cash flow $898.1m (10-Q, now filed). Zero drawn debt at 30 June 2026 with $1.0bn undrawn secured revolver. |
| What do we forecast? | Revenue growth of 34% demonstrated; a terminal operating margin of 30%; an exit multiple of 14.7x. |
| What does Street forecast? | FY2026 revenue consensus $3,792.2m -> $3,901.5m (up), FY2026 EPS $9.96 -> $10.17 (up); FY2027 revenue $4,494.3m -> $4,568.4m (up), FY2027 EPS $12.66 -> $12.17 (down — the raised spend guide flows into FY2027 EPS). |
| Where do we differ? | HOUSE TARGET $199.44 IS below STREET'S $213.13 AND THE ENTIRE GAP IS THE MULTIPLE: Street's average implies 4.83x EV/NTM-sales (their own revenue, same forward net cash) = the median of NBIX's own forward history; house uses 4.50x (~38th pctile) for the spend-guide/IRA de-rating. On revenue growth, the difference between what the price requires and what the business has demonstrated is +30.9 percentage points. |
| What is it worth? | Twelve-month target $199.40, +27% from the struck price. Scenario-weighted expected return net of costs +18.9%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| 27 October 2026 | Next results (date estimated, not issuer-confirmed) | Revenue and margin in line with, or above, the house path | A miss that moves the full-year path below the guided floor |
| Q3 2026 (~late October 2026) and Q4 2026 (~February 2027) | INGREZZA quarterly net product sales below $700m in either Q3 2026 or… | INGREZZA quarterly net product sales at or above $700m in either Q3 2026 or Q4 2026 | INGREZZA quarterly net product sales below $700m in either Q3 2026 or Q4 2026 |
| Q3 2026 (~late October 2026) | CRENESSITY quarterly net product sales below $190m in Q3 2026 — no… | CRENESSITY quarterly net product sales at or above $190m in Q3 2026 | CRENESSITY quarterly net product sales below $190m in Q3 2026 |
| Q3 2026 (~late October 2026) | VYKAT XR net product sales below $95m in Q3 2026, the first full… | VYKAT XR net product sales at or above $95m in Q3 2026, the first full quarter under NBIX ownership | VYKAT XR net product sales below $95m in Q3 2026, the first full quarter under NBIX ownership |
Dates marked as estimated are drawn from the company’s own reporting cadence, not from an announcement.
The Zydus Paragraph IV challenge to INGREZZA SPRINKLE breaks the settled 1 March 2038 generic wall years early on a franchise that is 80.5% of TTM revenue ($2,717.5m of $3,373.9m; $716.5m of $959.0m in Q2 2026 = 74.7%). If no stay attached, approval could come sooner. The New Jersey action was dismissed in favor of the Delaware proceeding. An adverse claim-construction or invalidity outcome on the shared valbenazine patent estate, a settlement dated materially before 2038, or an at-risk launch after stay expiry re-prices INGREZZA's terminal value permanently. There is no $2.6bn cash cushion any more: net cash is $481.7m post-Soleno.
Estimated probability 18%, against the 54% level at which the position would be resized. It sits within that level.
Falsifiable and fundamental — not one of them is a price condition.
On approach to the $199.40 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | The Zydus Paragraph IV challenge to INGREZZA SPRINKLE breaks the settled 1 March 2038 generic wall years early on a franchise that is 80.5% of TTM revenue ($2,717.5m of $3,373.9m; $716.5m of $959.0m in Q2 2026 = 74.7%). |
| Momentum | Met | Does price action support or complicate entry timing? |
| Catalyst | Not determined | Time works for a long; the calendar is dense and now materially SHARPER than the prior run: the Zydus binary has a derived date (~Sep 2027) where the prior record had none. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The strongest case for mispricing is that the business already delivers +30.9 percentage points more growth than the price requires. The most important unresolved uncertainty is the permanent-loss mechanism: the Zydus Paragraph IV challenge to INGREZZA SPRINKLE breaks the settled 1 March 2038 generic wall years early on a franchise that is 80.5% of TTM revenue ($2,717.5m of $3,373.9m; $716.5m of $959.0m in Q2 2026 = 74.7%). The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $137.71, which forces an immediate review.